MedTrace Logo

Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction

NCT04309994 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 307

Last updated 2020-03-17

No results posted yet for this study

Summary

The goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of MPS ® vs. Cardioplexol ®) regarding perioperative outcome and with special attention to cardiac markers in patients with a recent heart attack.

Conditions

  • Heart Attack
  • Cardioplegia Solution Adverse Reaction
  • Coronary Artery Bypass Grafting (CABG)

Interventions

OTHER

Myocardial protection system (MPS)

cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used

OTHER

Cardioplexol

cardioplegia solution

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Oliver Reuthebuch, Prof. Dr. med. · Cardiac Surgery Clinic, University Hospital Basel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-01
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04309994 on ClinicalTrials.gov